Iron dextran

Names

[ CAS No. ]:
9004-66-4

[ Name ]:
Iron dextran

[Synonym ]:
MFCD00081553
Ferric hydroxide dextran complex

Biological Activity

[Description]:

Iron dextran (Fe dextran) can be used in the study of iron-deficiency anemia in animals[1][2].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

[In Vivo]

Iron dextran (FeDex, IP, 4 weeks, 300 μL of 10 mg) treatment does not increase NSR iron but causes iron-trapping in the tetinal vasculature[1]. Four weeks of IP FeDex injection in 2-month-old WT mice leads to iron accumulation in the RPE and rVECs, but did not increase NSR iron or induce photoreceptor degeneration[1]. Animal Model: Wild-type (WT) and RS-HepcKO mice[1]. Dosage: IP. Administration: 300 μL of 10 mg daily for 5 days each week for 2 or 4 weeks. Result: Markedly elevated iron levels in 2 and 4 weeks of FeDex-injection groups, by 365.4-fold and 405.4-fold, respectively, compared with PBS controls.

[References]

[1]. Wanting Shu, et al. Iron Accumulates in Retinal Vascular Endothelial Cells But Has Minimal Retinal Penetration After IP Iron Dextran Injection in Mice. Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4378-4387.

[2]. D. R. ZIMMERMAN, et al. INJECTABLE IRON-DEXTRAN AND SEVERAL ORAL IRON TREATMENTS FOR THE PREVENTION OF IRONDEFICIENCY ANEMIA OF BABY PIGS x. Journal of Animal Science, Volume 18, Issue 4, November 1959, Pages 1409–1415.

Chemical & Physical Properties

[ Molecular Formula ]:
H₂O₄S_.Fe

[ Molecular Weight ]:
1347.364

[ Exact Mass ]:
1346.576050

[ Appearance of Characters ]:
solution

Safety Information

[ Symbol ]:

GHS07, GHS08

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H317-H350

[ Precautionary Statements ]:
P201-P280-P308 + P313

[ Hazard Codes ]:
Xn

[ Risk Phrases ]:
R40;R42/43

[ Safety Phrases ]:
S23;S26;S45;S36/S37/S39

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
-

[ RTECS ]:
NI2200000

Articles

Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status

Exp. Hematol. 41(6) , 539-46, (2013)

Numerous studies have shown the antiproliferative effect of iron chelating agents (ICAs), which have been used traditionally in patients with secondary iron overload (SIO). Because the in vivo model f...

[Importance of the different i.v. iron generations for everyday medical practice].

MMW Fortschr. Med. 155 Suppl 1 , 18-24, (2013)

Iron deficiency and anaemia occur in particular in women or as comorbid conditions to a varietyof chronic diseases. Besides oral preparations, parenteral iron therapies are also available for the trea...

Use of intravenous iron supplementation in chronic kidney disease: an update.

Iran. J. Kidney Dis. 7(1) , 9-22, (2013)

Iron deficiency is an important clinical concern in chronic kidney disease (CKD), giving rise to iron-deficiency anemia and impaired cellular function. Oral supplementation, in particular with ferrous...

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.